← All trials
NCT07292207
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2026
- Primary completion
- Nov 30, 2028
- Completion date
- Aug 31, 2031
- First posted
- Dec 18, 2025
- Last posted
- Dec 18, 2025
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nagoya City UniversityLead sponsor
- Aichi Medical UniversityCollaborator
- Japanese Foundation for Cancer ResearchCollaborator
- Nagoya City UniversityOfficial
- Nagoya City UniversitySponsor investigator
- National Cancer Center, JapanCollaborator
- Tohoku UniversityCollaborator
- University of TsukubaCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.